Connection

Michael Gold to Survival Rate

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Survival Rate.
Michael Gold
Connection Strength
0.940
Survival Rate
  1. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
    View in: PubMed
    Score: 0.138
  2. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
    View in: PubMed
    Score: 0.112
  3. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.110
  4. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.105
  5. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.081
  6. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
    View in: PubMed
    Score: 0.076
  7. Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
    View in: PubMed
    Score: 0.064
  8. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.062
  9. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1981-5.
    View in: PubMed
    Score: 0.036
  10. Pacing for patients with congestive heart failure and dilated cardiomyopathy. Cardiol Clin. 2000 Feb; 18(1):55-66.
    View in: PubMed
    Score: 0.034
  11. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
    View in: PubMed
    Score: 0.029
  12. Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. Eur J Heart Fail. 2017 07; 19(7):950-957.
    View in: PubMed
    Score: 0.028
  13. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
    View in: PubMed
    Score: 0.027
  14. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.022
  15. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
    View in: PubMed
    Score: 0.009
  16. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.